VX-950 Oral Hepatitis C Protease Inhibitor
Monday, January 9th, 2006The Vertex VX-950 does look impressive even at this early stage of clinical trials. I wouldn’t hold your breath but it looks worthy of keeping an eye on.
Data announced today by Vertex show that VX-950, an investigational hepatitis C virus (HCV) protease inhibitor, dosed in combination with pegylated interferon alfa-2a , achieved a [...]